Boston Scientific (BSX) Q3 2026 Earnings Call Transcript

Boston Scientific reported Q3 2026 sales of $5.138 billion, up 1.5% year over year, and adjusted EPS of $0.73, down 3% and below its $0.80–$0.82 guidance range. An eight-business-day cybersecurity disruption reduced organic revenue growth by an estimated 300 bps and adjusted EPS by $0.07; management expects a further 200–300 bps revenue headwind and $0.04–$0.05 EPS impact in Q4 as customer inventory normalizes. The company lowered its 2026 organic growth outlook to approximately 3.75% and said revenue and adjusted EPS growth will be challenging in 2027, citing EP and WATCHMAN competition and China pricing pressure. It expects more than $500 million in restructuring savings over three years and is targeting improved growth in 2028; Penumbra's acquisition closing is now expected in early 2027.

Analysis

The investable issue is not the temporary cyber disruption; it is that two formerly high-growth franchises now create a multi-quarter mix and execution problem. Even if volumes recover elsewhere, weaker EP and WATCHMAN contribution plus China price erosion can constrain gross-margin recovery, while restructuring savings arrive with a lag and may be absorbed by continued investment. That makes a quick snapback in earnings less likely than a snapback in shipments.

The market may be treating 2027 as a trough with a fairly visible 2028 product-led recovery. That recovery is less certain: share losses persist until launches arrive, several pipeline dates have slipped, and clinical, regulatory, and execution milestones remain. Penumbra could improve the consolidated growth profile after close, but acquisition growth should not be confused with an organic BSX turn; financing costs also complicate the EPS bridge. The upside case is that management’s 2027 framing is deliberately cautious and that launches plus savings produce better operating leverage than expected. The key near-term test is whether EP and WATCHMAN stabilize before the promised pipeline arrives.

Key Decisions for Investors

• Underweight BSX, or use rallies ahead of the next formal 2027 outlook to initiate a modest short, with a 3–6 month horizon. The thesis is persistent mix and share pressure—not a repeat of the cyber event. Keep the position sized for medtech-wide risk rather than assuming a straight-line decline.
• Falsify the short if successive updates show EP share losses easing, WATCHMAN procedure trends improving, and gross-margin guidance stabilizing despite China pricing. Conversely, further deterioration in those measures or another material launch delay would strengthen the thesis.
• Avoid treating restructuring savings as a near-term EPS catalyst until delivery is visible in operating margins; verify realized savings against implementation costs and continued R&D investment. A sales recovery without margin recovery would be a warning that the earnings trough is later or deeper than framed.
• Keep PEN on a deal-timing watchlist rather than making a directional position from the stated strategic rationale. Reassess after regulatory clearance and updated financing/dilution terms; the missing inputs are closing certainty, post-close EPS impact, and the acquired business’s growth trajectory.